Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Jyoti Malhotra,Petros Nikolinakos,Ticiana Leal,Jonathan M. Lehman,Daniel Morgensztern,Jyoti D. Patel,John Wrangle,Giuseppe Curigliano,Eric Dansin,Laurent Greillier,Melissa Lynne Johnson,Neal Ready,Gilles Robinet,Satwant Lally,Shekman Wong,Emin Avsar,Ricardo Valenzuela,Charity D. Scripture,Giovanni Selvaggi,Benjamin Besse

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

2019

8516Background: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting DLL3, a Notch ligand expressed in SCLC but not normal tissue. Nivo ± Ipi has activity in 2L+ SCLC. Prelimin...

Keywords:

Ipilimumab
Conjugate
Nivolumab
Extensive stage
Pathology
Rovalpituzumab tesirine
Oncology
Medicine
Notch ligand
Internal medicine
normal tissue

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations